^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SAR440234

i
Other names: SAR440234, SAR 440234
Associations
Trials
Company:
Sanofi
Drug class:
CD3 agonist, CD123 inhibitor
Related drugs:
Associations
Trials
over2years
CD123-CODV-TCE bispecific T-cell engager for acute myeloid leukemia (AML): Activity on primary AML and safety in non-human primates (AACR 2022)
Importantly, following the dose-escalation scheme 0.1/1/3/3 µg/kg, only limited cytokine release after the 4th administration was observed, suggesting that mitigation of cytokine release can be obtained by progressive intra-monkey dose escalation. Taken together, these results indicate that CD123-CODV-TCE leads to potent and specific leukemic cancer cell killing independently of CD123 receptor density and E:T ratio, and that studies monitoring cytokine release in monkeys can be useful for future clinical development of TCEs in the setting of R/R AML.
Clinical
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD123 (Interleukin 3 Receptor Subunit Alpha)
|
CD123 positive • CD123 expression
|
SAR440234
almost3years
Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager CD123-CODV-TCE for Treatment of Acute Myeloid Leukemia (TCT-ASTCT-CIBMTR 2022)
We demonstrated that the combination of DC/AML fusion vaccine and CD123TCE led to increase in tumor specific Tc immunity, both ex-vivo and in a xenograft murine model when compared to uneducated Tc with CD123TCE or educated Tc with isotype control. Most significantly, the combination treatment was shown to eradicate AML in this model with all animals remaining AML several months post inoculation.
IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD123 (Interleukin 3 Receptor Subunit Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • GZMB (Granzyme B)
|
SAR440234
3years
Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia (ASH 2021)
We demonstrated that the combination of DC/AML fusion vaccine and CD123TCE led to increase in tumor specific T cell immunity, both ex-vivo and in a xenograft murine model when compared to uneducated T cells with CD123TCE or educated T cells with isotype control molecule. Most significantly, the combination treatment was shown to eradicate AML in this model with all animals remaining disease-free several months post inoculation.
IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD4 (CD4 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9) • GZMB (Granzyme B)
|
CD8 expression • IFNG expression
|
SAR440234